| Summaryev3 Inc. (EVVV) SWOT Profile is a | | | | Feb 18, 2010: ev3 Reports Net Income Of $41.9 |
| comprehensive business, functional and strategic | | | | Million In 2009 |
| analysis of ev3 Inc.. The profile delves into the | | | | Scope |
| operations of the company to present an in-depth | | | | - Examines key information about company for |
| analysis of the various aspects related to its business. | | | | business intelligence. |
| It analyzes the company's business structure, | | | | - The company's core strengths and weaknesses and |
| operations, major products and services, prospects, | | | | areas of development or decline are analyzed and |
| locations and subsidiaries, executive biographies and | | | | presented objectively. Business, strategic and |
| key competitors. The hallmark of the profile is the | | | | operational aspects are taken into account. |
| detailed strategic analysis of the company. This | | | | - Opportunities available to the company are sized up |
| highlights and presents an unbiased view of its key | | | | and its growth potential assessed. Competitive and |
| strengths and weaknesses and the potential | | | | or technological threats are highlighted. |
| opportunities and threats. The profile helps you | | | | - The profile contains valuable and critical company |
| formulate strategies that augment your business by | | | | information – business structure and operations, |
| understanding your partners, customers and | | | | the company history, major products and services, |
| competitors better.ev3 Inc. (ev3) is a global medical | | | | prospects, key competitors, key employees, |
| device company engaged in developing innovative | | | | executive biographies, important locations and |
| technologies and solutions for the endovascular | | | | subsidiaries. |
| treatment of peripheral vascular and neurovascular | | | | - The profile provides detailed financial ratios for the |
| diseases. The company principally operates in the US, | | | | past five years as well as interim ratios for the last |
| Canada, Europe and other countries. | | | | five interim periods for major public companies. |
| Key Recent Developments | | | | - Financial ratios presented for major public companies |
| Apr 08, 2010: MEDRAD Signs Supply Agreement With | | | | include revenue trends, profitability, growth, margins |
| ev3 For Definitive AR Pilot Study | | | | and returns, liquidity and leverage, financial position |
| Apr 08, 2010: Medrad Signs Supply Agreement With | | | | and efficiency ratios. |
| ev3 For Definitive AR Pilot Trial | | | | |